Home > Blog > Research > Equity Research: Sanofi
On April 28, 2021 Sanofi reported strong first quarter earnings, above market expectations, driven by growth across Dupixent and Vaccines.
For the first quarter, total sales volume decreased by 4.3% on a reported basis, to €8,591 million. The top line performance was negatively impacted by exchange rate movements, with a total negative effect of 6.7 percentage points. Excluding the impact of the currency movement, total sales increased by 2.4%, as strong growth across speciality care (+15.3%) and vaccines (+5.3%) more than offset sales declines across consumer health care (-7.3%) and general medicines (-3.8%). Click here to access the report

Disclaimer

The information provided on this website is being provided solely for educational and informational purposes and should not be construed as investment advice, advice concerning particular investments or investment decisions, or tax or legal advice. Similarly, any views or opinions expressed on this website are not intended and should not be construed as being investment, tax or legal advice or recommendations. Investment advice should always be based on the particular circumstances of the person to whom it is directed, which circumstances have not been taken into consideration by the persons expressing the views or opinions appearing on this website. Calamatta Cuschieri Investment Services Ltd has not verified and consequently neither warrants the accuracy nor the veracity of any information, views, or opinions appearing on this website. You should always take professional investment advice in connection with, or independently research and verify, any information that you find or views or opinions which you read on our website and wish to rely upon, whether for the purpose of making an investment decision or otherwise. CC does not accept liability for losses suffered by persons as a result of information, views, or opinions appearing on this website.

Calamatta Cuschieri Investment Services Ltd is licensed to conduct investment services business under the Investments Services Act by the MFSA and is also registered as a Tied Insurance Intermediary under the Insurance Distribution Act.